Discover and read the best of Twitter Threads about #spatialbiology
Most recents (5)
In #biotech #stocks news, today we review $TXG @10xGenomics , one of the companies in the #SingleCell and #SpatialBiology sectors.
10x Genomics is a biotechnology company that develops and markets solutions for omics analysis of single cell and spatial biology samples. The company offers several product lines:
The Chromium platform is used for single-cell gene expression analysis, immune profiling, and genome sequencing. It allows researchers to study gene expression at the single-cell level, which can provide insights into cell behavior and disease progression.
In #JPM2023 news, $NSTG NanoString presented on January 11, 2023. Started in single-cell gene expression, now expanding into #SpatialBiology. They see a $3B+$3B market opportunity both on the NGS-based and the Imaging-based tech respectively. 
The GeoMx is the NGS-based spatial biology solution, akin to the 10X Genomics Visium (and Visium HD in the future), with 25+ instruments in the pipe. CosMx is the imaging-based equivalent (Xenium in 10x portfolio), with about 80 instruments already in the pipe.
Lots of slides to describe CosMx, which is the newest and fastest growing instrument for $NSTG NanoString. High Plex, up to 1000-plex RNA assay, but also does Protein, FFPE Compatible, Tunable Throughput, Complete Informatics (AtoMx). Now 180 cummulative orders.
In #JPM2023 news, $AKYA Akoya Biosciences presented with their #SpatialBiology solutions. Here the 3 instruments lined up from Discovery to Translational to Clinical segments.
Instrument numbers: 229 PhenoCyclers, 83 PhenoImager Fusions, and 551 PhenoImager HTs, Mantras & Vectras, as of September 30, 2022.
They see the 3 segment TAMs in the $3B, $4B and $7B range. I wonder if there are others leaning more on the clinical for their TAM predictions, rather than having earlier segments already accounting for so much.
In #JPM2022 news, $TECH Bio-Techne is presenting. The company has started a play in #SpatialBiology using ACD probes.
They describe an "Ultraplex Discovery" mode with 100s-1000s of RNA molecules (or probes?)
The main play of interest for me from Bio-Techne is Liquid Biopsies with their Exosome-based assays. They want to expand to other cancers, e.g. Colorectal Cancer.
Latest Wolpin-Nowak lab paper on single cell, in situ protein-based characterization of transcriptional subtypes in pancreatic cancer now out in @CR_AACR aacrjournals.org/cancerres/arti…
Led by outstanding postdoc Hannah Williams with assistance from Andressa Dias Costa (@Andress84886647), Jinming Zhang, Sri Raghavan, and Peter Winter (@peterswinter) at @DanaFarber_Hale.
We designed an 8-plex immunofluoresence assay to infer tumor transcriptional subtype using three basal and three classical markers in standard FFPE tissue sections of pancreatic cancer.
